The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index.
Race-Based Therapeutics
Abstract
Are we moving into a new era of race-based therapeutics? The publication, in this issue of the Journal, of the African-American Heart Failure Trial (A-HeFT) (pages 2049–2057), a clinical trial of a medication intended for a single racial group, poses this awkward question. The study's most striking finding — that the addition of isosorbide dinitrate and hydralazine to conventional therapy for heart failure reduced relative one-year mortality by 43 percent among blacks — will provoke wide discussion. The trial's sponsor, NitroMed, which holds a patent on the fixed-dose combination of isosorbide dinitrate and hydralazine that was used, posits that heart . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Social Isolation and Health, with an Emphasis on Underlying Mechanisms
Cacioppo, J. T., & Hawkley, L. C. (2003) · Perspectives in Biology and Medicine · doi:10.1353/pbm.2003.0049 · Cited by 887
The Nazi Doctors: Medical Killing and the Psychology of Genocide, by Robert Jay Lifton
Kuper, L. (1987) · Political Science Quarterly · doi:10.2307/2151532 · Cited by 791
Carson, P., Ziesche, S., Johnson, G., & Cohn, J. N. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90001-5 · Cited by 533
Research works printed but not linked: 1
- Kahn J, 2004, Yale J Health Policy Law Ethics, 4, 1
Cited by
Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation
Ballard, R. A., Truog, W. E., Cnaan, A., Martin, R. J., Ballard, P. L., Merrill, J. D., Walsh, M. C., Durand, D. J., Mayock, D. E., Eichenwald, E. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061088 · Cited by 484
Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., & Fuselli, S. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000239974.69464.f2 · Cited by 398
Misrepresenting Race — The Role of Medical Schools in Propagating Physician Bias
Amutah, C., Greenidge, K., Mante, A., Munyikwa, M., Surya, S. L., Higginbotham, E., Jones, D. S., Lavizzo-Mourey, R., Roberts, D., Tsai, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmms2025768 · Cited by 317
Recalibrating the use of race in medical research
Ioannidis, J. P. A., Powe, N. R., & Yancy, C. (2021) · JAMA · doi:10.1001/jama.2021.0003 · Cited by 296
Genetic Ancestry in Lung-Function Predictions
Kumar, R., Seibold, M. A., Aldrich, M. C., Williams, L. K., Reiner, A. P., Colangelo, L., Galanter, J., Gignoux, C., Hu, D., Sen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907897 · Cited by 256
Stormy Weather: Race, Gene Expression, and the Science of Health Disparities
Krieger, N. (2005) · American Journal of Public Health · doi:10.2105/ajph.2005.067108 · Cited by 200
Epstein, S. (2008) · Social Studies of Science · doi:10.1177/0306312708091930 · Cited by 183
Race, Gender, and Genetic Technologies: A New Reproductive Dystopia?
Roberts, D. E. (2009) · Signs · doi:10.1086/597132 · Cited by 157
Mondry, A., Loh, M. C. S., Liu, P., Zhu, A.-L., & Nagel, M. (2005) · BMC Nephrology · doi:10.1186/1471-2369-6-1 · Cited by 148
“If this holds true, studies aiming at drug development based on genomic traits must be scrutinized rigorously as therapeutic recommendations may be valid for selected subpopulations only[ 64 ].”
Promising pessimism: Reading the futures to be avoided in biotech
Tutton, R. (2011) · Social Studies of Science · doi:10.1177/0306312710397398 · Cited by 142
“Despite successfully achieving this regulatory approval, the company was soon subjected to intense criticism on a number of fronts, such as the design and conduct of its clinical trial (Kahn, 2008) and the claim that it was exploiting entrenched health disparities amongst racial/ethnic groups in the US for its own com…”
BackgroundAddressing the “Research Gap” in Special Education Through Mixed Methods
Klingner, J. K., & Boardman, A. G. (2011) · Learning Disability Quarterly · doi:10.1177/0731948711417559 · Cited by 179
“Patients respond differently to the same treatment for many reasons, some of which medical experts indicate seem to be related to race (Bloche, 2004; Committee on Pharmacokinetics and Dmg Interaction in the Elderly, Institute of Medicine, 1997; Harder, 2005).”
BackgroundRacial, Cultural, and Ethnic Factors Influencing End-of-Life Care
Crawley, L. M. (2005) · Journal of Palliative Medicine · doi:10.1089/jpm.2005.8.s-58 · Cited by 134
“66 Finally, if the correlations were such that we could use race as a proxy, then what racial classifications would adequately describe the distributions of genetic variation?”
Mainous, A. G., Majeed, A., Koopman, R. J., Baker, R., Everett, C. J., Tilley, B. C., & Díaz, V. A. (2006) · Public Health Reports · doi:10.1177/003335490612100112 · Cited by 125
“Public Health Reports / January‐February 2006 /V olume 121 to define five categories representing a continuum of acculturation from Spanish language only ( 5 ), primarily Spanish (6‐10), about equal use of Spanish and English (11‐15), primarily English (16‐20), and nearly all English (21‐25).”
BackgroundBiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Temple, R., & Stockbridge, N. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00010 · Cited by 110
Pharmacogenetics and geographical ancestry: implications for drug development and global health
Daar, A. S., & SINGER, P. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1559 · Cited by 103
“In addition, there will always be market-based incentives if entrepreneurs identify an opportunit”
BackgroundCole, R. T., Kalogeropoulos, A. P., Georgiopoulou, V. V., Gheorghiade, M., Quyyumi, A. A., Yancy, C. W., & Butler, J. (2011) · Circulation · doi:10.1161/circulationaha.110.012781 · Cited by 88
Implications of Pharmacogenomics for Drug Development and Clinical Practice
Ginsburg, G. S. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.20.2331 · Cited by 74
BiDil: Assessing a Race-Based Pharmaceutical
Brody, H., & Hunt, L. M. (2006) · The Annals of Family Medicine · doi:10.1370/afm.582 · Cited by 78
Sterling, R., Henderson, G. E., & Corbie-Smith, G. M. (2006) · American Journal of Public Health · doi:10.2105/ajph.2005.069286 · Cited by 65
Correlates of weapon carrying among high school students in the United States
Muula, A. S., Rudatsikira, E., & Siziya, S. (2008) · Annals of General Psychiatry · doi:10.1186/1744-859x-7-8 · Cited by 60
Collection of Data on Patients' Race and Ethnic Group by Physician Practices
Wynia, M. K., Ivey, S. L., & Hasnain‐Wynia, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmsb0910799 · Cited by 56
Angus, D. C., Linde‐Zwirble, W. T., Tam, S. W., Ghali, J. K., Sabolinski, M. L., Villagra, V. G., Winkelmayer, W. C., & Worcel, M. (2005) · Circulation · doi:10.1161/circulationaha.105.563882 · Cited by 54
Psychiatric genetics – the new era: genetic research and some clinical implications
Prathikanti, S., & Weinberger, D. R. (2005) · British Medical Bulletin · doi:10.1093/bmb/ldh055 · Cited by 50
The Water Surrounding the Iceberg: Cultural Racism and Health Inequities
Michaels, E. K., Lam-Hine, T., Nguyen, T. T. X., Gee, G. C., & Allen, A. M. (2023) · Milbank Quarterly · doi:10.1111/1468-0009.12662 · Cited by 58
Hollenbach, J. A., Saperstein, A., Albrecht, M. C., Vierra‐Green, C., Parham, P., Norman, P. J., & Maiers, M. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135960 · Cited by 48
Haseltine, S. J., Pae, J., Ehrlich, J. R., Shammas, M. C., & Radcliffe, N. M. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.02509.x · Cited by 47
Inhaled Nitric Oxide for Preterm Infants — Who Benefits?
Martin, R. J., & Walsh, M. C. (2005) · New England Journal of Medicine · doi:10.1056/nejme058124 · Cited by 46
Organic nitrates in cardiovascular disease.
Bode‐Böger, S. M., & Kojda, G. (2005) · PubMed · Cited by 56
McNamara, D. M., Taylor, A. L., Tam, S. W., Worcel, M., Yancy, C. W., Hanley‐Yanez, K., Cohn, J. N., & Feldman, A. M. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.016 · Cited by 43
Lynch, J., Bevan, J. L., Achter, P., Harris, T. M., & Condit, C. M. (2008) · New Genetics and Society · doi:10.1080/14636770701843634 · Cited by 44
“The premier race-based medication is NitroMed’s BiDil, a heart disease medication intended solely for African-Americans (Bloche 2004).”
BackgroundMethodInfluentialClinical characteristics of South Asian patients hospitalized with heart failure.
Singh, N., & Gupta, M. (2005) · PubMed · Cited by 42
Race and Ethnicity in Medical Research: Requirements Meet Reality
Winker, M. A. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00065.x · Cited by 46
Mauro, M., Allen, D. S., Dauda, B., Molina, S. J., Neale, B. M., & Lewis, A. C. F. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.11.001 · Cited by 50
The Roles of Counseling Psychologists in Reducing Health Disparities
Tucker, C. M., Ferdinand, L. A., Mîrșu-Păun, A., Herman, K. C., Delgado-Romero, E. A., van den Berg, J. J., & Nielsen, J. J. (2007) · The Counseling Psychologist · doi:10.1177/0011000007301687 · Cited by 42
“These and other findings have prompted the recent development of controversial race-specific medications (Bloche, 2004; Taylor et al., 2004) and promoted a campaign of genetic research geared toward reducing and/or eliminating health disparities (Collins et al.”
BackgroundJawa, A., Nachimuthu, S., Pendergrass, M. L., Asnani, S., & Fonseca, V. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1632 · Cited by 38
Genomics and the Conundrum of Race: Some Epistemic and Ethical Considerations
Maglo, K. N. (2010) · Perspectives in biology and medicine · doi:10.1353/pbm.0.0171 · Cited by 36
Jones, D. S. (2011) · Journal of the History of Medicine and Allied Sciences · doi:10.1093/jhmas/jrr046 · Cited by 38
Asian ethnicity is associated with decreased pregnancy rates following intrauterine insemination
Lamb, J. D., Huddleston, H. G., Purcell, K. J., Modan, A., Farsani, T. T., Dingeldein, M. A., Vittinghoff, E., & Fujimoto, V. Y. (2009) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60081-8 · Cited by 36
Jawa, A., Nachimuthu, S., Pendergrass, M., Asnani, S., & Fonseca, V. A. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.05.003 · Cited by 35
“The issue of race-based choice of therapy is controversial (Bloche, 2004).”
BackgroundMau, M. K. L. M., West, M. R., Shara, N. M., Efird, J. T., Alimineti, K., Saito, E., Sugihara, J. G., & Ng, R. C. K. (2007) · Ethnicity and Health · doi:10.1080/13557850601081720 · Cited by 31
“2001; Powe 2003; Bloche 2004; Lakkis & Weir 2004; Taylor et al .”
Crawford, D. C., Ritchie, M. D., & Rieder, M. J. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.5.487 · Cited by 29
Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges
Jones, D. S., & Perlis, R. H. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600642895 · Cited by 32
Pharmacogenetic studies of antidepressant response: how far from the clinic?
Perlis, R. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.12.004 · Cited by 28
Whittle, J., Kressin, N. R., Peterson, E. D., Orner, M. B., Glickman, M. E., Mazzella, M., & Petersen, L. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.059 · Cited by 32
Settle, K., Taylor, R., Wolf, J. S., Kwok, Y., Cullen, K. J., Carter, K., Ord, R. A., Zimrin, A. B., Strome, S. E., & Suntharalingam, M. (2009) · Cancer · doi:10.1002/cncr.24168 · Cited by 27
“Continued smoking after treatment‡ 21 (20) 16 (17) .”
Pharmacogenomics and the Challenge of Health Disparities
Lee, S. S. (2009) · Public Health Genomics · doi:10.1159/000189630 · Cited by 24
“Based on these results, the FDA recommended on June 16, 2005, that BiDil be approved specifically for the treatment of heart failure in ‘self-identified black’ patients.To be clear, BiDil was ‘rescued’ by post-hoc analysis when the results of its 2 earlier trials were rejected by the FDA. The race-based indication for…”
Racial disparities in risk factors for thrombosis
Itakura, H. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000167746.26145.53 · Cited by 24
Using genotyping to predict responses to anti-hypertensive treatment
Kurland, L., LIND, L., & Melhus, H. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.07.008 · Cited by 23
Bussey‐Jones, J., Henderson, G. E., Garrett, J. M., Moloney, M., Blumenthal, C., & Corbie-Smith, G. M. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0883-7 · Cited by 22
“Supporters of such work suggest that it may lead to improved health for individuals and populations, proposing that a better understanding of disease risk and targeted pharmacogenomic innovations are examples of this potential.(1,2) However, others express concern about the lack of clarity and consistency around the a…”
BackgroundThe politics of ‘wrongful life’ itself: discursive (mal)practices and Tay-Sachs disease
Reuter, S. Z. (2007) · Economy and Society · doi:10.1080/03085140701254290 · Cited by 21
“…effects of this practice (see, for example, the Munro decision outlined below, which rests entirely on a reified notion of ‘The Jewish Tay-Sachs Carrier’) are also important, especially given the proliferation of ‘race’-based therapies and research (see Epstein 2004; Bloche 2004; Cooper et al .”
BackgroundKrimsky, S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60052-x · Cited by 21
Primary Care Physicians’ Attitudes Regarding Race-Based Therapies
Frank, D., Gallagher, T. H., Sellers, S. L., Cooper, L. A., Price‐Haywood, E. G., Odunlami, A. O., & Bonham, V. L. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1190-7 · Cited by 21
Égalité, N., Özdemir, V., & Godard, B. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1115 · Cited by 21
“The much-disputed claims made in support of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), a drug that was not developed by pharmacogenomics guidance, nonetheless appropriated notions of genetics by advancing innate causes for differential drug response among African–American heart failure patients [18].”
ResultMentioning race at the beginning of clinical case presentations: a survey of US medical schools
Nawaz, H., & Brett, A. S. (2009) · Medical Education · doi:10.1111/j.1365-2923.2008.03257.x · Cited by 19
Efficacy of beta-blockade after isolated blunt head injury: Does race matter?
Bukur, M., Mosheni, S., Ley, E. J., Salim, A., Margulies, D. R., Talving, P., Δημητριάδης, Δ., & Inaba, K. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318241bc5b · Cited by 21
Petersen, K. E., Prows, C. A., Martin, L. J., & Maglo, K. N. (2014) · Public Health Genomics · doi:10.1159/000362359 · Cited by 26
What's right (and wrong) with racially stratified research and therapies.
Sade, R. M. (2007) · PubMed · Cited by 17
Applying justice in clinical trials for diverse populations
Tilburt, J. C., Ford, J. G., Howerton, M. W., Gary‐Webb, T. L., Lai, G. Y., Bolen, S. D., Baffi, C. R., Wilson, R. F., Tanpitukpongse, T. P., Powe, N. R., et al. (2007) · Clinical Trials · doi:10.1177/1740774507079440 · Cited by 17
Racial medicine: here to stay?
Weigmann, K. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400654 · Cited by 17
“In June 2005, the US Food and Drug Administration (FDA; Rockville, MD) approved the first drug labelled for a racially identified population: BiDil® (NitroMed; Lexington, MA, USA) for the treatment of chronic heart failure in African-Americans.”
BackgroundPractical concerns that arise from using race/ethnicity as ‘the most reliable proxy available’
Smart, A. (2005) · Critical Public Health · doi:10.1080/09581590500048432 · Cited by 16
“An open discussion about this longstanding problem has become apposite, even imperative, given the current debate regarding the use of race/ethnicity in genetics and medicine (e.g. Schwartz, 2001; Feldman, Lewontin & King, 2003; Phimister, 2003; Bloche, 2004; Nature Genetics, 2004a, 2004b; Pearce, Foliaki, Sporle & Cu…”
BackgroundFranks, P. W. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.134 · Cited by 19
Maglo, K. N., Rubinstein, J., Huang, B., & Ittenbach, R. F. (2014) · AJOB Empirical Bioethics · doi:10.1080/23294515.2014.907371 · Cited by 16
“Yet critics countered that race is utterlymeaningless in genomics and evidence-basedmedicine, and that race-based therapy is driven by corporate interests in a race niche market (Bloche 2004; Duster 2007; Graves 2011; Roberts 2008; 2012; Rusert and Royal 2011).”
BackgroundInfluentialShooting the messenger: the science and politics of ethnicity research
Singh, S. P. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.058685 · Cited by 15
PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, K. E., Gammal, R. S., Karnes, J. H., Afanasjeva, J., Anderson, K. C., Barreto, E. F., Beavers, C. J., Bhat, S., Birrer, K. L., Chahine, E. B., et al. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1107 · Cited by 15
Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews
Liu, P., Ross, J. S., Ioannidis, J. P. A., Dhruva, S. S., Vasiliou, V., & Wallach, J. D. (2019) · Clinical Trials · doi:10.1177/1740774519887148 · Cited by 15
Democratizing Strategies for Industry-Funded Medical Research: A Cautionary Tale
Pinto, M. F. (2018) · Philosophy of Science · doi:10.1086/699720 · Cited by 16
Carmody, M. S., & Anderson, J. R. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000250840.15645.fb · Cited by 15
“holds a patent for the use of the fixed-dose combination in blacks until the year 2020.(47) According to the American College of Cardiology and the American Heart Association’s 2005 guidelines for the diagnosis and management of chronic heart failure in adults, it is a class IIa recommendation (weight of evidence/opin…”
The Human Genome Project: An Historical Perspective for Social Workers
Saunders, M. A. (2011) · Social Work in Public Health · doi:10.1080/19371918.2011.579041 · Cited by 13
“This drug has been found to be ineffective in treating heart disease in the general population, but effective in treating Black heart patients with low levels of nitric-oxide drug, a condition that is more common in Black than non-White persons (Bloche, 2004).”
BackgroundCallier, S., Cunningham, B. A., Powell, J., McDonald, M. A., & Royal, C. D. M. (2019) · Health Equity · doi:10.1089/heq.2018.0074 · Cited by 13
Bloche, M. G. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00069.x · Cited by 13
Reuter, S. Z. (2006) · The Canadian Journal of Sociology · doi:10.1353/cjs.2006.0061 · Cited by 12
Vines, A. I., & Godley, P. A. (2004) · North Carolina Medical Journal · doi:10.18043/ncm.65.6.341 · Cited by 15
Legal Regulation of the Use of Race in Medical Research
Lillquist, E., & Sullivan, C. A. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00067.x · Cited by 13
Group-Based and Personalized Care in an Age of Genomic and Evidence-Based Medicine: A Reappraisal
Maglo, K. N. (2012) · Perspectives in biology and medicine · doi:10.1353/pbm.2012.0006 · Cited by 12
“Because corporate rationale prevailed over scientific logic, the phase III trial became a race-based trial that included only African American patients (”
BackgroundJones, D. D. (2022) · Health Equity · doi:10.1089/heq.2021.0141 · Cited by 15
Mainous, A. G., Baker, R., Majeed, A., Koopman, R. J., Everett, C. J., Saxena, S. K., & Tilley, B. C. (2006) · Public Health Reports · doi:10.1177/003335490612100317 · Cited by 11
Race and end‐stage renal disease in the United States Medicare population: The disparity persists
Tomson, C., Foley, R. N., Li, Q., Gilbertson, D. T., Xue, J. L., & Collins, A. J. (2008) · Nephrology · doi:10.1111/j.1440-1797.2008.01010.x · Cited by 11
Beyond Best Practices: Strict Scrutiny as a Regulatory Model for Race-Specific Medicines
Obasogie, O. K. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.296.x · Cited by 13
State of Play of Pharmacogenetics and Personalized Medicine in Heart Failure
Parry, H., Doney, A. S. F., Colin N.A. Palmer, & Lang, C. C. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12030 · Cited by 9
Vlaar, A. P. J., van Son, W. J., & Bakker, W. W. (2008) · Nephron Physiology · doi:10.1159/000183178 · Cited by 9
Avera, E. (2009) · Anthropology and Medicine · doi:10.1080/13648470902940648 · Cited by 9
“The marketability of racially specific treatment – the lure of a future with personalised drugs, for example – may diminish incentives for such an investigation (Bloche 2004, 2036–2037).”
BackgroundDeliberating about race as a variable in biomedical research
Niekerk, A. A. V. (2011) · South African Medical Journal · doi:10.7196/samj.4702 · Cited by 8
Law, Race, and Biotechnology: Toward a Biopolitical and Transdisciplinary Paradigm
Roberts, D. E. (2013) · Annual Review of Law and Social Science · doi:10.1146/annurev-lawsocsci-102612-134009 · Cited by 12
Özdemir, V. (2010) · Advances in biological psychiatry · doi:10.1159/000317296 · Cited by 8
Clustering humans: on biological boundaries
Lorusso, L., & Boniolo, G. (2008) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2007.12.005 · Cited by 8
“Bloche, 2004 ). Indeed, earlier studies (cf.”
BackgroundThe Future of Pharmacogenetics in the Treatment of Heart Failure
Anwar, M. S., Iskandar, Z., Parry, H., Doney, A. S. F., Palmer, C. N., & Lang, C. C. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.120 · Cited by 9
Race as a variable in pharmacogenomics science: from empirical ethics to publication standards
Özdemir, V., Graham, J., & Godard, B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830a48f3 · Cited by 7
The year in heart failure: 2004
Massie, B. M. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.01.001 · Cited by 7
Overview of Chronopharmaceutics
Youan, B.-B. C. (2009) · Wiley eBooks · doi:10.1002/9780470498392.ch1 · Cited by 7
Recommendations for empirical syndemics analyses: A stepwise methodological guide
Bulled, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38931 · Cited by 6
Ethics and Research Assessing the Relative Roles of Genes and the Environment*
DeCamp, M. W., & Sugarman, J. (2004) · Accountability in Research · doi:10.1080/08989620490891359 · Cited by 5
Have we witnessed the rise and fall of race-specific drugs?
Coons, S. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.03.022 · Cited by 5
Lynch, J. (2008) · Western Journal of Communication · doi:10.1080/10570310802210130 · Cited by 5
“The most prominent example is the heart medication BiDil that is approved for use by African Americans only (Bloche, 2004).”
BackgroundThe Biological Basis of Performativity of Identity - Linking Scientific Evidence to Social Theory
Constantine, G. R. (2017) · Journal of Ethnic and Cultural Studies · doi:10.29333/ejecs/82 · Cited by 5
“These studies and behavioral genetic studies have to a large extent showed that these differences and similarities can be found in biological body systems and morphological characteristics (Bloche, 2004; Mountain & Risch, 2004).”
BackgroundThe Politics of Race and Science: Conservative Colorblindness and the Limits of Liberal Critique
Roberts, D. E. (2015) · Du Bois Review Social Science Research on Race · doi:10.1017/s1742058x15000041 · Cited by 4
Fernández‐Santander, A., Luna, F., Santiago, C., Rodríguez, M. T., Bandrés, F., Ruiz, J. R., Lucía, A., & Gómez‐Gallego, F. (2009) · Annals of Human Biology · doi:10.1080/03014460903051658 · Cited by 4
Introducing Social and Ethical Perspectives on Gene—Environment Research
Henderson, G. E. (2008) · Sociological Methods & Research · doi:10.1177/0049124108323536 · Cited by 4
“1999; Wood 2001), while many describe concerns about the validity of early findings and potentially negative social impacts (Bloche 2004; Condit 2001; Kahn 2005; Kaufman 2008; Marx-Stölting 2006; Sankar and Kahn 2005).”
BackgroundVilchez, G., Dai, J., Kumar, K., Mundy, D., Kontopoulos, E. V., & Sokol, R. J. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1342795 · Cited by 3
Fernández‐Santander, A., Luna, F., Santiago, C., Rodríguez, M. T., Bandrés, F., Ruiz, J. R., Lucía, A., & Gómez‐Gallego, F. (2010) · Annals of Human Biology · doi:10.3109/03014460903051658 · Cited by 4
Harder, B. (2005) · Science News · doi:10.2307/4016318 · Cited by 3
Metadata
- Authors
- Bloche, M. G.
- Affiliations
- Georgetown University (US)
- Corresponding author
- Bloche, M. Gregg
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2035-2037
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2135617416
- Cited by
- 150
- References
- 6
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 2 · 2012: 15
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Anthropology › Race, Genetics, and Society
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- racial medicine, heart failure, isosorbide dinitrate, hydralazine, fixed-dose combination, racial disparities in mortality, patent litigation
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Black or African American, Drug Combinations, Drug Industry, Drug Therapy, Combination, Enalapril, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Patents as Topic, Pharmacogenetics, United States, United States Food and Drug Administration, Vasodilator Agents, Drug Approval, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.